Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/6714
Type: Journal article
Title: Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin
Author: Bouralexis, S.
Clayer, M.
Atkins, G.
Labrinidis, A.
Hay, S.
Graves, S.
Findlay, D.
Evdokiou, A.
Citation: International Journal of Oncology, 2004; 24(5):1263-1270
Publisher: Professor D A Spandidos
Issue Date: 2004
ISSN: 1019-6439
1791-2423
Abstract: Chemotherapy is an established treatment modality for bone sarcomas such as osteosarcoma (OS). However, the use of chemotherapy in high-grade soft tissue sarcomas remains controversial, with the most active chemotherapeutic agent, doxorubicin (DOX), reported to have a response rate of, at best only 34% and most studies reporting lower response rates. Apo2L/TRAIL is a member of the tumour necrosis factor (TNF) family of cytokines and induces death of tumour cells, but not normal cells. Its potent apoptotic activity is mediated through cell surface death domain-containing receptors, DR4/TRAIL-R1 and DR5/TRAIL-R2. We investigated the efficacy of Apo2L/TRAIL as a single agent, and in combination with clinically relevant chemotherapeutic drugs, in fresh isolates of primary malignant cells obtained from biopsy material. The data presented here demonstrate that, in a range of primary bone related tumours, as well as soft tissue sarcomas, chemotherapeutic agents were only moderately effective, in terms of induction of cell death. Apo2L/TRAIL alone had little or no effect on any bone-related tumour or sarcoma in culture. In contrast, the combination of Apo2L/TRAIL and chemotherapeutic drugs produced a significant increase in tumour cell death, with DOX and Apo2L/TRAIL proving to be the most effective combination. These data suggest the potential for Apo2L/TRAIL to increase the effectiveness of chemotherapeutic drugs in bone and soft tissue sarcomas, while perhaps concurrently allowing a reduction in the exposure to drugs such as DOX, and a consequent reduction in toxicity. The synergistic action between these two different classes of agents has yet to be tested in vivo but may prove clinically relevant in the treatment of this refractive class of malignancies.
Keywords: Tumor Cells, Cultured; Humans; Giant Cell Tumor of Bone; Osteosarcoma; Sarcoma; Bone Neoplasms; Doxorubicin; Tumor Necrosis Factor-alpha; Membrane Glycoproteins; Combined Modality Therapy; Transfection; Drug Resistance, Neoplasm; Adolescent; Adult; Aged; Aged, 80 and over; Middle Aged; Child; Female; Male; Apoptosis Regulatory Proteins; TNF-Related Apoptosis-Inducing Ligand
RMID: 0020040328
Published version: http://www.spandidos-publications.com/ijo/
Appears in Collections:Orthopaedics and Trauma publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.